romiplostim
Selected indexed studies
- Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia. (J Clin Oncol, 2019) [PMID:31545663]
- Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature. (Cancer Med, 2024) [PMID:39135303]
- A Review of Romiplostim Mechanism of Action and Clinical Applicability. (Drug Des Devel Ther, 2021) [PMID:34079225]
_Worker-drafted node — pending editorial review._
Connections
romiplostim is a side effect of
Sources
- Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia. (2019) pubmed
- Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature. (2024) pubmed
- A Review of Romiplostim Mechanism of Action and Clinical Applicability. (2021) pubmed
- Romiplostim. (2011) pubmed
- Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia. (2026) pubmed
- Romiplostim. (2009) pubmed
- A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. (2021) pubmed
- Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatment. (2024) pubmed
- Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. (2020) pubmed
- Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study. (2021) pubmed